http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021123560-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61034c7eb0b07d0261a1f3db3ce745d3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2020-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d850a0472b3cbbf26b6199b236114c43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8acffdb9b4972c4b81087cae7aadf73c |
| publicationDate | 2021-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021123560-A |
| titleOfInvention | Claudin-2 binding small molecule compound with anticancer drug resistance improving effect |
| abstract | PROBLEM TO BE SOLVED: To create a cancer adjuvant therapeutic agent effective for cancer treatment and to improve the treatment result of cancer. SOLUTION: A drug containing ledipasvir or a pharmaceutically acceptable salt thereof as an active ingredient and effective for improving the hypoxic state of cancer cells and enhancing the sensitivity of cancer cells to anticancer drugs is provided. .. [Selection diagram] None |
| priorityDate | 2020-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.